Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1A | P54750 | 3/20 | 0.38 |
| ▸ | PDE1B | Q01064 | 3/20 | 0.38 |
| ▸ | PDE1C | Q14123 | 3/20 | 0.38 |
| ▸ | PDE2A | O00408 | 1/20 | 0.38 |
| ▸ | PDE5A | O76074 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TYMS | P04818 | 1/20 | 0.31 |
| ▸ | CDK4 | P11802 | 3/20 | 0.31 |
| ▸ | CCND1 | P24385 | 3/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10004739 | 0.84 | CCNE2 (0.34) | PDE1APDE1BPDE1CPDE5AKMT2A | |
| SCHEMBL10003985 | 0.82 | PDE5A (0.36) | PDE1APDE1BPDE1CPDE2APDE5A | |
| SCHEMBL10004091 | 0.78 | CDK4 (0.35) | PDE1APDE1BPDE1CPDE2AKMT2A | |
| SCHEMBL10004729 | 0.72 | HKDC1 (0.53) | LMNAMAPK1SMN1; SMN2 | |
| SCHEMBL10003931 | 0.67 | MAPT (0.40) | KMT2AHPGDLMNAMAPK1 | |
| SCHEMBL10004957 | 0.67 | LMNA (0.45) | KMT2AHPGDLMNAMAPK1SMN1; SMN2 | |
| SCHEMBL10003130 | 0.64 | BCL2 (0.38) | PDE1APDE1BPDE1CKMT2AHPGD | |
| SCHEMBL9825854 | 0.62 | KMT2A (0.33) | KMT2A | |
| SCHEMBL9165974 | 0.62 | MAPT (0.37) | PDE5AKMT2ALMNASMN1; SMN2 | |
| SCHEMBL18283297 | 0.62 | CDK4 (0.44) | PDE2ACDK4CCND1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2471793-B1 | FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2016-10-05 | — | — | EP | disclosed |
| US-8614208-B2 | Fused heterocyclic ring derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-12-24 | — | — | US | disclosed |
| US-20120214795-A1 | FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-23 | — | — | US | disclosed |
| EP-2471793-A1 | FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2012-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214795-A1 | FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF | SMO, GLI1, SHH | PDE1A 1487/4885PDE1B 1445/4885PDE1C 1748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.